Alpha 2.0
Login Register
» Authors » Yusuke Tachibana

Yusuke Tachibana

Explore the profile of Yusuke Tachibana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 57
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Radiology
Top 10 Co-Authors
Tadaaki Yamada
Takayuki Takeda
Koichi Takayama
Masaki Ishida
Shinsaku Tokuda
Shinsuke Shiotsu
Kenji Morimoto
Yuki Katayama
Nozomi Tani
Hayato Kawachi
Published In
Thorac Cancer
Cancer Sci
Diagnostics (Basel)
Cancer Lett
Infect Dis (Lond)
Affiliations
Soon will be listed here.
Recent Articles
11.
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
Takeda T, Yamada T, Tanimura K, Nakano T, Ishida M, Tachibana Y, et al.
Diagnostics (Basel) . 2021 Dec; 11(12). PMID: 34943412
The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring () gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have...
12.
Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study
Tani N, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Sato I, et al.
Multidiscip Respir Med . 2021 Apr; 16(1):736. PMID: 33815789
Background: The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks...
13.
Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer
Ogura Y, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Tani N, et al.
Thorac Cancer . 2020 Oct; 12(1):97-105. PMID: 33124197
Background: First-line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression-free survival (PFS) outcomes among patients with non-small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate...
14.
Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature
Sato I, Mizuno H, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, et al.
Medicina (Kaunas) . 2020 Aug; 56(8). PMID: 32796633
Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are life-threatening dermatologic adverse events in the same category, caused by a delayed-type drug hypersensitivity reaction. Although skin toxicity is common during...
15.
Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Sato I, Tani N, et al.
Thorac Cancer . 2020 Jul; 11(9):2740-2742. PMID: 32706170
Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE)...
16.
Clinical features in active tuberculosis patients with effects on T-SPOT.TB assay results
Uda S, Ono S, Yuba T, Tachibana Y, Goda S, Matsuyama A, et al.
Infect Dis (Lond) . 2019 Sep; 52(1):58-60. PMID: 31512548
No abstract available.